Takeda Pharmaceutical Co Stock Five Year Return
| TKPHF Stock | USD 27.64 0.44 1.62% |
Takeda Pharmaceutical Co fundamentals help investors to digest information that contributes to Takeda Pharmaceutical's financial success or failures. It also enables traders to predict the movement of Takeda Pink Sheet. The fundamental analysis module provides a way to measure Takeda Pharmaceutical's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Takeda Pharmaceutical pink sheet.
Takeda |
Takeda Pharmaceutical Co Company Five Year Return Analysis
Takeda Pharmaceutical's Five Year Return is considered one of the best measures to evaluate fund performance, especially from the mid and long term perspective. It shows the total annualized return generated from holding equity for the last five years and represents capital appreciation of the investment, including all dividends, losses, and capital gains distributions.
More About Five Year Return | All Equity Analysis
Five Year Return | = | (Mean of Monthly Returns - 1) | X | 100% |
Current Takeda Pharmaceutical Five Year Return | 3.99 % |
Most of Takeda Pharmaceutical's fundamental indicators, such as Five Year Return, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Takeda Pharmaceutical Co is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Although Five Year Returns can give a sense of overall investment potential, it is recommended to compare equity performance with similar assets for the same five year time interval. Similarly, comparing overall investment performance over the last five years with the appropriate market index is a great way to determine how this equity instrument will perform during unforeseen market fluctuations.
| Competition |
According to the company disclosure, Takeda Pharmaceutical Co has a Five Year Return of 3.99%. This is much higher than that of the Healthcare sector and significantly higher than that of the Drug Manufacturers—Specialty & Generic industry. The five year return for all United States stocks is notably lower than that of the firm.
Did you try this?
Run Companies Directory Now
Companies DirectoryEvaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals |
| All Next | Launch Module |
Takeda Fundamentals
| Return On Equity | 0.0477 | |||
| Return On Asset | 0.0247 | |||
| Profit Margin | 0.07 % | |||
| Operating Margin | 0.13 % | |||
| Current Valuation | 75.53 B | |||
| Shares Outstanding | 1.56 B | |||
| Shares Owned By Insiders | 1.20 % | |||
| Shares Owned By Institutions | 41.35 % | |||
| Price To Earning | 27.54 X | |||
| Price To Book | 0.97 X | |||
| Price To Sales | 0.01 X | |||
| Revenue | 3.57 T | |||
| Gross Profit | 2.44 T | |||
| EBITDA | 1.05 T | |||
| Net Income | 230.06 B | |||
| Cash And Equivalents | 645.99 B | |||
| Cash Per Share | 417.82 X | |||
| Total Debt | 4.14 T | |||
| Debt To Equity | 0.81 % | |||
| Current Ratio | 1.18 X | |||
| Book Value Per Share | 3,973 X | |||
| Cash Flow From Operations | 1.12 T | |||
| Earnings Per Share | 1.33 X | |||
| Price To Earnings To Growth | 0.58 X | |||
| Number Of Employees | 47.35 K | |||
| Beta | 0.7 | |||
| Market Capitalization | 50.37 B | |||
| Total Asset | 13.18 T | |||
| Retained Earnings | 1.57 T | |||
| Working Capital | 675.58 B | |||
| Current Asset | 1.48 T | |||
| Current Liabilities | 808.72 B | |||
| Annual Yield | 0.04 % | |||
| Five Year Return | 3.99 % | |||
| Net Asset | 13.18 T | |||
| Last Dividend Paid | 180.0 |
About Takeda Pharmaceutical Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Takeda Pharmaceutical Co's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Takeda Pharmaceutical using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Takeda Pharmaceutical Co based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
Additional Information and Resources on Investing in Takeda Pink Sheet
When determining whether Takeda Pharmaceutical is a good investment, qualitative aspects like company management, corporate governance, and ethical practices play a significant role. A comparison with peer companies also provides context and helps to understand if Takeda Pink Sheet is undervalued or overvalued. This multi-faceted approach, blending both quantitative and qualitative analysis, forms a solid foundation for making an informed investment decision about Takeda Pharmaceutical Co Stock. Highlighted below are key reports to facilitate an investment decision about Takeda Pharmaceutical Co Stock:Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Takeda Pharmaceutical Co. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in rate. You can also try the Premium Stories module to follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope.